Health AI Central
Share:
Peer-Reviewed Publication
JACC Case Rep2025;30(26):104876.September 3, 2025Case Reports

Facilitating Earlier Diagnosis of Pulmonary Hypertension Using a Novel Noninvasive Diagnostic.

Rieta Aben1, Timothy Burton2, Farhad Fathieh2, Navid Nemati2, Horace R Gillins3, Ian Shadforth3, Shyam Ramchandani2, Charles R Bridges4, Adrian Cheong5, Felix Sogade1
1Atrium Health Navicent, Macon, Georgia, USA.
2Analytics for Life, Toronto, Canada.
3CorVista Health, Bethesda, Maryland, USA.
4CorVista Health, Bethesda, Maryland, USA. Electronic address: cbridges@corvista.com.
5The Heart Clinic, Hong Kong, China.
PubMed PMC DOI PDF

Abstract

BACKGROUND: Pulmonary hypertension (PH) is frequently underdiagnosed due to limitations of transthoracic echocardiography, particularly when tricuspid regurgitant velocity (TRV) is unmeasurable. CorVista PH (point-of-care test for pulmonary hypertension [POC-PH]) is a novel, Food and Drug Administration-cleared point-of-care diagnostic with 82% sensitivity and 92% specificity for identifying mean…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.